A detailed history of Bank Of America Corp transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Bank Of America Corp holds 118,864 shares of PRTA stock, worth $2.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
118,864
Previous 240,343 50.54%
Holding current value
$2.47 Million
Previous $5.95 Million 58.79%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$19.54 - $26.15 $2.37 Million - $3.18 Million
-121,479 Reduced 50.54%
118,864 $2.45 Million
Q1 2024

May 15, 2024

SELL
$24.75 - $40.66 $1.16 Million - $1.91 Million
-47,012 Reduced 16.36%
240,343 $5.95 Million
Q4 2023

Feb 14, 2024

BUY
$32.31 - $52.32 $4.15 Million - $6.72 Million
128,493 Added 80.88%
287,355 $10.4 Million
Q2 2023

Aug 14, 2023

SELL
$48.26 - $78.59 $19.6 Million - $31.9 Million
-405,579 Reduced 71.85%
158,862 $10.8 Million
Q1 2023

May 12, 2023

BUY
$46.97 - $58.27 $20.8 Million - $25.8 Million
442,770 Added 363.91%
564,441 $27.4 Million
Q4 2022

Feb 10, 2023

BUY
$52.05 - $65.0 $2.01 Million - $2.51 Million
38,574 Added 46.42%
121,671 $7.33 Million
Q3 2022

Nov 14, 2022

BUY
$25.16 - $60.63 $446,665 - $1.08 Million
17,753 Added 27.17%
83,097 $5.04 Million
Q2 2022

Aug 12, 2022

SELL
$22.73 - $39.98 $2.11 Million - $3.71 Million
-92,875 Reduced 58.7%
65,344 $1.77 Million
Q1 2022

May 16, 2022

SELL
$30.27 - $49.22 $311,266 - $506,129
-10,283 Reduced 6.1%
158,219 $5.79 Million
Q4 2021

Feb 08, 2022

BUY
$42.11 - $73.26 $5.68 Million - $9.88 Million
134,928 Added 401.88%
168,502 $8.32 Million
Q3 2021

Nov 15, 2021

BUY
$48.2 - $78.89 $840,174 - $1.38 Million
17,431 Added 107.98%
33,574 $2.39 Million
Q2 2021

Sep 13, 2021

BUY
$21.63 - $57.65 $349,173 - $930,643
16,143 New
16,143 $829,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $973M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.